The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
This facility marks a significant milestone in transforming the global food industr
Merck has also decided to end the favezelimab clinical development program
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
SPARC to receive 55% equity in Tiller Therapeutics
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Harnessing advanced data analysis for early detection, prevention and better outcomes
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Subscribe To Our Newsletter & Stay Updated
